Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.
Almarsson
Orn
O
TransForm Pharmaceuticals, Inc., 29 Hartwell Avenue, Lexington, MA 02421, USA. almarsson@transformpharma.com
Zaworotko
Michael J
MJ
D000143:Acids / Q000737:chemistry; D000577:Amides / Q000737:chemistry; D002264:Carboxylic Acids / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003460:Crystallization / Q000379:methods; D003461:Crystallography; D004355:Drug Stability; D006860:Hydrogen Bonding; D015394:Molecular Structure; D009930:Organic Chemicals / Q000737:chemistry; D004364:Pharmaceutical Preparations; D044367:Phase Transition; D013678:Technology, Pharmaceutical / Q000295:instrumentation / Q000379:methods*
D000143:Acids; D000577:Amides; D002264:Carboxylic Acids; D009930:Organic Chemicals; D004364:Pharmaceutical Preparations